Lobby organisation
Eli Lilly and Company
Company · Health & pharma · HQ: United States · Transparency Register entry
As of 7 November 2026, Eli Lilly and Company appears in 73 declared MEP meetings (46 different MEPs), most often with European People's Party.
In their own words
“Lilly is a leading innovative biopharmaceutical company that unites caring with discovery to make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.”
Read the rest of the statementShow less of the statement
“Headquartered in the US, Lilly has approximately 46,913 employees worldwide. In 2024 global revenue was approx. $45.04 billion, of which 24.4% as a percentage of sales was invested in Research and Development. Average cost to discover and develop a new drug: $2.6 billion. Average length of time from discovery to patient: 10 years. This data will be updated as soon as new annual report is available ( approx. April 2026) ( https://investor.lilly.com/financials.cfm )”
Stated goals from the organisation's own Transparency Register filing.
Who they meet, and when
Which groups they meet
Share of this organisation's 73 declared meetings, by the meeting MEP's political group.
Meetings by year
Declared meetings per calendar year, 2021–2026. Bar length is relative to its busiest year (33 in 2024). Hatched: 2026 is a part-year - the record runs to 6 Nov 2026.
Group is each MEP's current political group, not necessarily the one they sat with at the time. Shares are rounded to whole percent.
The MEPs they meet most
The 15 most recent declared meetings
| Date | MEP | Subject |
|---|---|---|
| 20 Oct 2026 | Tiemo Wölken | MDR/IVDR Revision and Biotech Act |
| 13 Oct 2026 | Tiemo Wölken | Biotech Act |
| 1 Oct 2026 | Aleksandar Nikolic | Rencontre avec Eli Lilly |
| 30 Sep 2026 | Aurelijus Veryga | European Neurological Health Strategy – Potential Pillars and Priorities |
| 28 Sep 2026 | Lukas Mandl | Health Systems in Europe |
| 2 Sep 2026 | Sirpa Pietikäinen | Neurological Health Strategy |
| 2 Sep 2026 | Maria Guzenina | Exchange of views on MDR/IVDR revision |
| 1 Sep 2026 | Elena Nevado del Campo | Alzhéimer |
| 18 Aug 2026 | Lukas Mandl | EU Biotech Act |
| 24 Jun 2026 | Ruggero Razza | Incontro conoscitivo su priorità SANT |
| 8 Jun 2026 | Tiemo Wölken | Biotech Act |
| 28 Apr 2026 | Ingeborg ter Laak | Biotech Act |
| 19 Mar 2026 | Elena Nevado del Campo | Cardiovascular health |
| 18 Mar 2026 | Margarita de la Pisa Carrión | SANT COMMITTEE ONGOING WORK |
| 18 Mar 2026 | Anna Bryłka | diagnostics in Alzheimer’s disease |
Meeting an MEP is a normal part of democratic life; the record is shown so anyone can see it.